Caprion’s caStx 1-2 Antibodies Receive European And US Orphan Drug Designation For Treatment Of Shiga-Toxin Producing E. Coli

MONTREAL--(BUSINESS WIRE)--Dec. 20, 2005--Caprion Pharmaceuticals Inc. today announced that caStx1 and caStx2, investigational therapeutic monoclonal antibodies, have been granted orphan drug status for the treatment of Shiga-toxin producing E. Coli (STEC) infections by the European Medicines Agency (EMEA) and the United States (US) Food and Drug Administration (FDA). This designation provides Caprion with, among other benefits, ten years of potential market exclusivity if the product is approved for marketing in the European Union (EU) and seven years exclusivity if approved in the US.